Paul Kent

Paul Kent

Auto-generated profile, based on publicly available information

Paul Kent

Rush University Medical Center

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2001 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HKHoward M. Katzenstein
Howard M. Katzenstein
PKPaul M. Kent
Paul M. Kent
WLWendy B. London
Wendy B. London
SCSusan L. Cohn
Susan L. Cohn
PURPOSE: To investigate whether the rate of neurologic recovery or the incidence of long-term sequelae differed for children with neuroblastoma (NB) initially treated with chemotherapy versus surgical decompression with laminectomy, we reviewed the Pediatric Oncology Group (POG) experience. PATIENTS AND METHODS: A retrospective review of children diagnosed with intraspinal NB registered on POG NB Biology Protocol 9047 was performed. Survival, neurologic outcome, and orthopedic sequelae were evaluated according to age of the patient at diagnosis, stage of disease, duration and severity of neurologic symptoms, and therapeutic intervention. RESULTS: Between May 1990 and January 1998, 83 children with intraspinal NB were entered onto the study. Five-year survival for this cohort of patients was 71% ± 9%. Forty-three (52%) of the patients had neurologic symptoms at diagnosis. After treatment, six of 15 severely affected patients, who presented with paralysis, completely recovered neurologic function. Two of five patients with moderate deficits, consisting of paresis and bowel/bladder dysfunction, completely recovered neurologic function. Seventeen of 22 assessable children, who had mild symptoms comprised of paresis alone, fully recovered. Seven of 24 assessable patients who had undergone laminectomy developed scoliosis, whereas spinal deformities were only detected in one of 49 assessable patients managed without laminectomy (P = .001). CONCLUSION: The frequency of complete neurologic recovery in children with intraspinal NB inversely correlated with the severity of the presenting neurologic deficits. The rate of neurologic recovery was similar for patients treated with chemotherapy compared to those managed with laminectomy. Fewer orthopedic sequelae were observed in the children managed with chemotherapy than were seen in children managed with laminectomy.

28 October 2011 in Pediatric Radiology
Verified
Journal Article
Closed access
PDF file
SBSharon E. Byrd
Sharon E. Byrd
JAJacques Abramowicz
Jacques Abramowicz
PKPaul Kent
Paul Kent
RKRobert E. Kimura
Robert E. Kimura
DEDean Elias
Dean Elias
PHPeter T. Heydeman
Peter T. Heydeman

9 March 2021 in Oncology
Verified
Journal Article
Closed access
PDF file
SGSara Gottlieb
Sara Gottlieb
COClaire O’gRady
Claire O’gRady
AGAriel Gliksberg
Ariel Gliksberg
PKPaul Kent
Paul Kent
Introduction: There are no standard systemic therapies for the treatment of fibrolamellar carcinoma (FLC), as surgery remains the only definitive option. We share our experiences using systemic “triple therapy” (TT) with 5-fluorouracil, interferon, and nivolumab for the treatment of relapsed, refractory, metastatic, or unresectable FLC. Methods: Data from all patients who received TT from May 2018 to July 2020 were reviewed to assess response, survival, and toxicity. Results: A total of 22 patients were treated with TT, of which 14 (median age of 21 years) were evaluable. They received a median of 18 cycles (8–44). At the time of analysis, the median progression-free survival was 9 months (4.5–26), 29% longer than prior to TT, with 5 patients achieving clinical remission, 8 patients stable or improving, and 1 progression. Overall objective response (clinical remission + partial response) was 50% and tumor control rate (clinical remission + partial response + stable disease) was 93%. Two patients withdrew from treatment due to side effects. Discussion/Conclusion: Our early results support TT as a promising medical option to slow disease progression and prolong survival in high-risk patients with FLC. TT can be administered in the outpatient setting and has shown good tolerability. Further longitudinal data is needed to confirm outcomes, especially in patients still early in their treatment.

11 December 2019 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
PDF file
HTHale M. Thompson
Hale M. Thompson
JCJennifer A Coleman
Jennifer A Coleman
RIRavi M Iyengar
Ravi M Iyengar
SPShay Phillips
Shay Phillips
PKPaul M Kent
Paul M Kent
NSNeeral Sheth
Neeral Sheth
Background Transgender medicine is an emergent subfield with clearly identified educational gaps. Aims This manuscript evaluates a gender-affirming healthcare curriculum for second-year medical (M2) students. Methods Students received a survey assessing Gender Identity Competency in terms of skills, knowledge and attitudes regarding transgender and gender non-conforming (TGNC) issues. The authors administered the survey before and after the delivery of the curriculum. The curriculum included five online modules, a quiz, a 3-hour case-based workshop and a 2-hour interactive patient-provider panel. Results Approximately 60% of M2 students (n=77) completed both preassessments and postassessments. The following showed a statistically significant improvement from preassessment to postassessment: student Gender Identity Competency, t(76) = −11.07, p<0.001; skills, t(76) = −15.22, p<0.001; and self-reported knowledge, t(76) = −4.36, p<0.001. Negative attitudes did not differ (p=0.378). Interest in TGNC issues beyond healthcare settings did not change (p=0.334). M2 students reported a significant change in experience role-playing chosen pronouns in a clinical setting, t(76) = −8.95, p<0.001. Conclusions The curriculum improved students’ gender-affirming medical competency, knowledge and skills. The development of a sustained, longitudinal curriculum is recommended in addition to the continuing education of faculty to reinforce this expanding knowledge and skills base and to address discomfort working with this population.

5 November 2016 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CKChristopher Kuo
Christopher Kuo
PKPaul M. Kent
Paul M. Kent
ALAntonio D. Logan
Antonio D. Logan
KTKaren B. Tamulonis
Karen B. Tamulonis
KDKristen L. Dalton
Kristen L. Dalton
RMRebecca E. Mcfall
Rebecca E. Mcfall

1 July 2019 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
ODOlivia M. Danforth
Olivia M. Danforth
KTKaren Tamulonis
Karen Tamulonis
KVKimberly Vavra
Kimberly Vavra
COCaleb Oh
Caleb Oh
ABArlen Brickman
Arlen Brickman
PKPaul Kent
Paul Kent
Pseudomyogenic hemangioendothelioma (PMH) is a rare neoplasm with vascular and sarcomatous elements, unpredictable course, and uncommon metastatic or fatal potential. Although systemic chemotherapy has been reported with variable success, generally accepted treatment is aggressive surgery with wide margins. Evidence-based treatment options are lacking, and lack of clear prognostic features poses a risk of undertreatment or overtreatment with associated morbidity and mortality. We report the use of initial systemic therapy with oral sirolimus (SIR) and IV zoledronic acid (ZA) to induce a sustained clinical response and avoidance of amputation in a 6-year-old boy. At 37 months after diagnosis, our patient remains in sustained clinical remission as documented by x-ray, MRI, and PET-CT with return of normal mobility/activity and resolution of swelling and pain. Literature review identified 20 cases of pediatric and young adult patients with PMH, of which 7 received some form of systemic therapy. To the best of our knowledge, our patient represents the youngest reported case of PMH and the first successful and limb-sparing utilization of systemic chemotherapy as primary treatment for PMH.